Noxxon Pharma

Noxxon Pharma
Aktiengesellschaft
Founded 1997
Headquarters Berlin, Germany
Key people
  • Aram Mangasarian, CEO
  • J. Donald deBethizy, Chairman of the supervisory board
  • Jens P. Furste, Founder
Number of employees
 10 (2017)[1]
Website www.noxxon.com

Noxxon Pharma is a biotechnology company founded in 1997 in Berlin, Germany. The company is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa). Noxxon Pharma N.V. is listed on Euronext Growth Paris (ALNOX).

Noxxon Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to natural occurring D-RNA molecules. The company calls these agents Spiegelmers,[2][3] from Spiegel, the German word for "mirror."

The L-RNA are resistant to the natural RNA nuclease enzymes.[4]

Products

While no Spiegelmer is on the market yet, some candidates are in clinical trials. Noxxon's focus is on improving cancer treatment by targeting the tumor microenvironment.

A Spiegelmer (NOX-A12, olaptesed pegol) is under development as a combination therapy for a number of cancer indications. NOX-A12 targets CXCXL12 (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October, 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer lmmunotherapy Conference in New York, NY, USA.[5][6][7][8]

A different Spiegelmer (NOX-E36, emapticap pegol) has been tested for the treatment of a progressive kidney disease in diabetics, Diabetic nephropathy.[9] Favorable results were reported in June, 2014 in a company press release.[10] NOX-E36 targets MCP-1, also called CCL2.[4]

A third Spiegelmer (NOX-H94, lexaptepid pegol) has been in a clinical trial for the treatment of Anemia of chronic disease.[11][12]

References

  1. ↑ Investors. Noxxon.com. Retrieved on 2018-02-14.
  2. ↑ Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects". Curr Opin Drug Discov Dev. 6 (2): 253–61. PMID 12669461.
  3. ↑ Eulberg D, et al. (2006), 18, "Spiegelmers for Therapeutic Applications" (in German), The Aptamer Handbook (WILEY-VCH): pp. 417-42, ISBN 3-527-31059-2
  4. 1 2 Aram Mangasarian explains the elegant mirror image technology of NOXXON Pharma for extracellular targets
  5. ↑ Clinical trial number NCT03168139 for "Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer" at ClinicalTrials.gov
  6. ↑ Clinical trial number NCT01521533 for "NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma" at ClinicalTrials.gov
  7. ↑ Clinical trial number NCT01486797 for "NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia" at ClinicalTrials.gov
  8. ↑ https://www.noxxon.com/downloads/pressrel/2018-10-02_NOXXON_Presentation_NOX-A12_Trial_Data_Part1_New_York_EN.pdf
  9. ↑ Clinical trial number NCT01547897 for "NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria" at ClinicalTrials.gov
  10. ↑ http://www.noxxon.com/downloads/pressrel/2014-06-02_NOXXONs_Emapticap_Pegol_Study_Selected_for_Late_Breaking_Clinical_Trials_Symposium.pdf.
  11. ↑ Clinical trial number NCT01691040 for "Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer" at ClinicalTrials.gov
  12. ↑ Schwoebel F, et al. (March 2013). "The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys". Blood. 121 (12): 2311–5. doi:10.1182/blood-2012-09-456756. PMC 3606066. PMID 23349391.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.